Introduction
============

Due to increasing resistance, alternatives to mupirocin and chlorhexidine for decolonization of MRSA carriage need to be evaluated.

Objectives
==========

To evaluate the efficacy of polyhexanide (Prontoderm^®^) *vs* placebo in eliminating MRSA carriage at day 28 (D28) after the end of treatment.

Methods
=======

In a 1,900-bed teaching hospital, MRSA-colonized patients were randomized into a double-blind, placebo-controlled superiority trial. Patients were treated with either polyhexanide (antiseptic and surface-active substances; group I) or placebo (only surface-active substances; group P) applied to the anterior nares and skin for 10 days. The primary outcome was MRSA decolonization at D28 assessed by both intention-to-treat (\[ITT\] responder analysis) and per-protocol (PP) analysis (microbiological follow-up ± 7 days and topical treatment ≥ 5 days). Secondary outcomes included MRSA decolonization according to nasal MRSA carriage, safety and emergence of resistance.

Results
=======

Of 2590 patients screened, 146 patients (group I, 71; group P, 75) were randomized between January 2011 and July 2014. Primary outcome was missing for 11 (7.5%) patients. ITT analysis showed that 24/71 (33.8%) patients in group I *vs* 22/75 (29.3%) in group P were MRSA-free at D28 (risk difference, 4.5%; 95% CI, -10.6% to 19.5%; *P*=0.56). PP analysis confirmed the results with 19/53 (35.8%) decolonized polyhexanide-treated patients *vs* 17/56 (30.4%) in the placebo arm (risk difference, 5.5%; 95% CI, -12.2% to 23.0%; *P*=0.54). In the subgroup of MRSA nasal carriers, PP analysis showed that 6/15 (40.0%) patients in group I *vs* 2/11 (18.2%) in group P were decolonized (*P*=0.40). Nine serious adverse events occurred in group I *vs* 12 in group P; none was attributable to study medication. Emergence of polyhexanide resistance was not observed.

Conclusion
==========

This study suggests that under real-life conditions a single polyhexanide decolonization course is marginally effective in eradicating MRSA carriage.
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